2023-05-16 22:57:07
The complexity of marketing procedures makes it difficult for French people to access innovative medicines. Pauline Fournier/Le Figaro
DECRYPTION – Laboratories, patients and researchers are mobilizing around innovative treatments authorized in Europe but failed in France.
The controversy is mounting around the access of the French to innovative drugs. At the end of January, Keytruda (MSD), which should become this year the best-selling treatment in the world, was rejected by the High Authority for Health (HAS) to treat patients with rare endometrial cancer.. At the end of November, this was the case for cell therapy Carvykti (Janssen), prescribed to treat relapsed patients suffering from multiple myeloma, a rare blood cancer.
At the beginning of February, Retsevmo (Lilly), which treats advanced lung cancer, was in turn rejected as first-line treatment. These three drugs are therefore not used in France for these indications. In addition, three antimigraine drugs (Teva, Novartis, Lilly), widespread in Europe, are certainly authorized in France, but without being reimbursed there, while the price of the box exceeds 200 euros.
Read alsoGeneral mobilization against drug shortages
All these drugs have the common point of being innovative therapies. All have also been approved by…
This article is for subscribers only. You have 91% left to discover.
Want to read more?
Unlock all items immediately.
Already subscribed? Login
#France #restricts #access #drugs